Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Linifanib · 2 trials · 2 indications
The investigators will monitor each subject for clinical and lab evidence of adverse events on a routine basis through out the study. The investigators will question each subject regarding any adverse effects that they have experienced and record any events on the care report forms. All adverse events will be followed to a satisfactory clinical resolution.
Physical exam, blood pressure, pulse, body temperature will be measured and recorded on the case report forms.
MUGA
Chemistry, hematology, urinalysis lab tests will be measured and recorded on the case report forms. All clinically significant values will be followed by the investigator to a satisfactory clinical resolution.
Evaluation of vital signs, physical exams, clinical lab testing and adverse event monitoring.
| Arm | Type | Description |
|---|---|---|
| linifanib | EXPERIMENTAL | - |
| Arm A | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| linifanib | DRUG | QD daily |
| Carboplatin | DRUG | Given on Day 1 of every 21-day cycle |
| Paclitaxel | DRUG | Given on Day 1 of every 21-day cycle |
Inclusion Criteria 1. Subject has completed a previous study utilizing linifanib (per the criteria in the previous study) or was active and assigned to linifanib when the study was completed and the investigator believes that continued treatment with linifanib is in the best interest of the subject...
Top 20 of 84 competitors
Linifanib is an investigational small molecule being studied for the treatment of advanced solid tumors and non-small cell lung cancer. It is being developed by AbbVie Inc. and is currently in Phase 1 clinical development.
Linifanib is a small molecule that targets receptor tyrosine kinases, including vascular endothelial growth factor receptor and platelet-derived growth factor receptor. These targets are involved in tumor angiogenesis and growth.
Linifanib is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol ABBV.
Linifanib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy.
Linifanib has been studied in two completed Phase 1 trials. NCT01225302 evaluated linifanib in combination with carboplatin and paclitaxel in Japanese subjects with non-small cell lung cancer. NCT01413893 was an extension study in subjects with advanced or metastatic solid tumors.
Yes, Linifanib is also known as ABT-869. Clinical trial records refer to the drug as linifanib (ABT-869), confirming that these names refer to the same investigational agent.